Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/bjd.21779 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Psychometric Properties and Meaningful Change Thresholds of the Vitiligo Area Scoring Index.
JAMA Dermatol
October 2024
Department of Dermatology, Multicultural Dermatology Center, Henry Ford Health, Detroit, Michigan.
Importance: Defining meaningful improvement using the Total Vitiligo Area Scoring Index (T-VASI) and the Facial VASI (F-VASI) aids interpretation of findings from clinical trials evaluating vitiligo treatments; however, clear and clinically meaningful thresholds have not yet been established.
Objective: To assess concept validity and measurement performance of the T-VASI and F-VASI in patients with nonsegmental vitiligo and to identify meaningful change thresholds.
Design, Settings, And Participants: This mixed-methods study consisted of a secondary analysis of a phase 2 multicenter double-blind dose-ranging randomized clinical trial and embedded qualitative interviews conducted at 35 sites in Canada, France, Japan, and the US.
Article Synopsis
- The IDEOM Vitiligo Workgroup aims to create a standardized approach for reporting the severity of vitiligo, as current methods are inconsistent and lack uniformity.
- A literature review identified 50 clinical trials focusing on topical treatments for vitiligo, revealing various grading systems for measuring repigmentation and quality of life.
- The study suggests employing metrics like body surface area scoring and the Vitiligo Area Scoring Index to improve data collection, while also considering new factors like treatment burden and cost-effectiveness.
Assessing Participants' Experiences with Vitiligo from Patient Interviews.
Dermatol Ther (Heidelb)
September 2024
Henri Mondor University Hospital and Université Paris-Est Créteil Val de Marne, Paris, France.
Introduction: Vitiligo is an autoimmune disease, causing skin depigmentation. Individuals with vitiligo incur substantial psychosocial burden and have expressed frustration with their treatments. Here, we describe the burden of vitiligo and opinions on what constitutes meaningful change among participants of two qualitative interview studies.
View Article and Find Full Text PDFDisease Course, Treatment Patterns and Goals Among Patients with Non-segmental Vitiligo Across Europe and the United States.
Dermatol Ther (Heidelb)
July 2024
Department of Dermatology, AP-HP, Henri Mondor University Hospital, UPEC, Créteil, France.
Introduction: There is currently a lack of research regarding disease course and burden as well as treatment patterns and goals in patients with non-segmental vitiligo (NSV). The aim of this analysis was to evaluate disease course, treatment patterns and goals in patients with NSV.
Methods: This analysis used secondary data from the Adelphi Real World Vitiligo Disease Specific Programme 2021, specifically, a survey of physicians and their adult and adolescent patients with NSV.
Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo.
Drugs
May 2024
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Topical ruxolitinib 1.5% cream (Opzelura), a Janus kinase (JAK) inhibitor, is the first treatment to be approved in several countries for use in patients aged ≥ 12 years with non-segmental vitiligo. In the identical phase III TRuE-V1 and TRuE-V2 trials, significantly more ruxolitinib cream recipients were able to achieve statistically significant and clinically meaningful facial and total body repigmentation, as well as reductions in vitiligo noticeability, compared with vehicle recipients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!